Aldoxorubicin
Product Sizes
5 mg
£ POA
HY-16261-5MG
100 mg
£ POA
HY-16261-100MG
10 mg
£ POA
HY-16261-10MG
50 mg
£ POA
HY-16261-50MG
25 mg
£ POA
HY-16261-25MG
About this Product
- SKU:
- HY-16261
- Additional Names:
- INNO-206; DOXO-EMCH
- Application:
- Antibody Microarray
- CAS Number:
- 1361644-26-9
- Extra Details:
- Aldoxorubicin (INNO-206) is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor); which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
- Molecular Weight:
- 750.75
- Purity:
- 95.56
- References:
- [1]Eric Sanchez, et al. Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206. Clin Cancer Res.2012 18; 3856.|[2]Kratz, F. INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies. Current Bioactive Compounds, 2011, 7(1): 33-38(6)|[3]Graeser R, et al. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs. 2010 F|[4]Walker L, et al. Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative. Int J Pharm. 2012 Oct 15;436(1-2):825-32.
- Research Area:
- Cancer
- Shipping Conditions:
- Dry Ice
- Storage Conditions:
- -80[o]C; stored under nitrogen
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Conjugated Protein
- Pathway:
- Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage
